Tilbake til søkeresultatene

PES2020-Prosj.etabl.støtte H2020

Safe Hand Disinfection with Anti-microbial Effect for Hand Hygiene reducing Healthcare-Associated Infections (HAI) and treating eczema.

Tildelt: kr 74 999

Prosjektnummer:

304097

Prosjektperiode:

2019 - 2019

Midlene er mottatt fra:

Geografi:

Hundreds of millions of patients get annually Healthcare-Associated Infections (HAI) globally (WHO, 2009), leading to high mortality and financial losses for health systems and countries. Global cost data are far higher than $100 Bn. Healthcare workers’ (HCWs’) hands are the most common vehicle to cause HAI. Low compliance with hand hygiene standards amongst HCW (38,7%, WHO) lead to transmission of pathogens and HAI. Occupational Hand Eczema (OHE) is mainly caused by hand hygiene procedures leading to sickness absence and reduced QoL for HCWs. The most prevalent type is “Irritant Contact Eczema” (ICE) often found on HCW’s hands (prevalence up to 55%) and which origins from e.g. alcohol in ABHR (Alcohol-Based Hand Rub) which is the prevalent product (98%) in hospitals/healthcare institutions and that risk for getting OHE and reduced QoL. SoftOx Solutions AS is a Norwegian MedTech company that during 6 years of R&D has developed best-in-class antimicrobial products to fight biofilm infections in acute and chronic wounds including eczema. The innovation behind SafeDes is based on SoftOx’ patented technology using buffered acetic acid together with hypochlorous acid (HOCl) that give a stable liquid disinfectant with increased shelf-life proven in vitro and pre-clinically. In the SafeDes project SoftOx will carry out three clinical studies and also sort out all regulatory approvals. The SafeDes project will include WPs as CRO selection, Product quality, Phase I Clinical trial in healthy volunteers, Phase I/IIa clinical trial in patients with hand eczema (Safety and efficacy, PoC) and CDE Activities. The Global Hand Sanitizer Market for hand disinfectants is €894 Mn (2016) with a CAGR of 9.9% (Allied Market Research). Our preliminary sales estimates indicate minimum €72 Mn sale of SafeDes Preventive and SERS in Y5 after SERS’ market introduction in 2025 with a profit of €56,4 Mn for both.

Budsjettformål:

PES2020-Prosj.etabl.støtte H2020